Work

556TiP A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1078

Authors: N.J. Lakhani, I. Braña, V.K. Chiu, A. Dowlati, E.K. Lee, S.M. McGoldrick, A. Minchom, X. Tian, A. Patnaik

Institutions: Vall d'Hebron Institute of Oncology, Angeles Clinic and Research Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Dana-Farber Cancer Institute, Seagen (United States), Royal Marsden Hospital, South Texas Accelerated Research Therapeutics

Language: English

Topic: Glycosylation and Glycoproteins Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3202196643

FWCI: 0.067

Cites:

Cited by: 1

Related to: 10